PDF(Pubmed)
Abstract：
Systemic lupus erythematosus (SLE), an autoimmune disease, is among the most prevalent rheumatic autoimmune disorders. It affects autologous connective tissues caused by the breakdown of self-tolerance mechanisms. During the last two decades, stem cell therapy has been increasingly considered as a therapeutic option in various diseases, including parkinson\'s disease, alzheimer, stroke, spinal cord injury, multiple sclerosis, inflammatory bowel disease, liver disease, diabete, heart disease, bone disease, renal disease, respiratory diseases, and hematological abnormalities such as anemia. This is due to the unique properties of stem cells that divide and differentiate to the specialized cells in the damaged tissues. Moreover, they impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present manuscript, efficacy of stem cell therapy with two main types of stem cells, including mesenchymal stem cell (MSC), and hematopoietic stem cells (HSC) in animal models or human patients of SLE, has been reviewed. Taken together, MSC and HSC therapies improved the disease activity, and severity in kidney, lung, liver, and bone (improvement in the clinical manifestation). In addition, a change in the immunological parameters occurred (improvement in immunological parameters). The level of autoantibodies, including antinuclear antibody (ANA), and anti-double-stranded deoxyribonucleic acid antibodies (dsDNA Abs) reduced. A conversion of Th1/Th2 ratio (in favor of Th2), and Th17/Treg (in favor of Treg) was also detected. In spite of many advantages of MSC and HSC transplantations, including efficacy, safety, and increased survival rate of SLE patients, some complications, including recurrence of the disease, occurrence of infections, and secondary autoimmune diseases (SAD) were observed after transplantation that should be addressed in the next studies.
摘要：
系统性红斑狼疮(SLE),一种自身免疫性疾病,是最常见的风湿性自身免疫性疾病之一。它影响由自身耐受机制的破坏引起的自体结缔组织。在过去的二十年里，干细胞疗法越来越被认为是各种疾病的治疗选择，包括帕金森病,老年痴呆症,中风,脊髓损伤,多发性硬化症,炎症性肠病，肝病,Diabete,心脏病,骨病,肾脏疾病,呼吸系统疾病,以及贫血等血液学异常.这是由于干细胞在受损组织中分裂并分化为特化细胞的独特特性。此外，它们具有免疫调节特性，影响由免疫异常引起的疾病，例如风湿性自身免疫性疾病。在目前的手稿中，两种主要类型的干细胞治疗的疗效，包括间充质干细胞（MSC），和造血干细胞（HSC）在动物模型或人类SLE患者，已被审查。一起来看,MSC和HSC治疗改善了疾病活动，肾脏的严重程度，肺，肝脏,和骨骼（临床表现改善）。此外,发生了免疫学参数的变化（免疫学参数的改善）。自身抗体的水平，包括抗核抗体（ANA），和抗双链脱氧核糖核酸抗体（dsDNAAb）减少。Th1/Th2比率的转换（有利于Th2），并且还检测到Th17/Treg(有利于Treg)。尽管MSC和HSC移植有许多优点，包括功效，安全,提高了SLE患者的生存率，一些并发症,包括疾病的复发，感染的发生，移植后观察到继发性自身免疫性疾病（SAD），应在下一步研究中解决。
